Back to top

messenger-rna: Archive

Zacks Equity Research

Novavax (NVAX) Q3 Earnings Miss, Lowers '22 Sales Outlook

Novavax (NVAX) reports mixed results in second-quarter 2022. Management lowers guidance for 2022.

PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change BNTXPositive Net Change

Zacks Equity Research

Moderna's (MRNA) Lags on Q3 Earnings, Lowers '22 Sales Outlook

Moderna's (MRNA) third-quarter earnings miss expectations, while sales narrowly beat the mark. Shares declined in pre-market trading after management announced a guidance cut in COVID vaccine sales.

MRKPositive Net Change GILDNegative Net Change MRNAPositive Net Change

Zacks Equity Research

GSK's Q3 Earnings Beat, Ups 2022 Sales Outlook, Stock Up

GSK's (GSK) revenues benefit from the strong growth in sales across all segments. The company raises the full-year sales guidance for all its segment

GSKPositive Net Change JNJPositive Net Change PFEPositive Net Change HLNNegative Net Change

Zacks Equity Research

Moderna (MRNA) to Report Q3 Earnings: What's in the Cards?

Investors will likely focus on the progress of Moderna's (MRNA) late-stage pipeline candidates during the third-quarter earnings call, which can lower its dependence on COVID vaccine sales.

MRKPositive Net Change MRNAPositive Net Change HOOKPositive Net Change